Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Biomarkers of endothelial activation/dysfunction distinguish sub-groups of Ugandan patients with sepsis and differing mortality risks.

Clark DV, Banura P, Bandeen-Roche K, Liles WC, Kain KC, Scheld WM, Moss WJ, Jacob ST.

JCI Insight. 2019 Apr 23;5. pii: 127623. doi: 10.1172/jci.insight.127623.

2.

Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study.

Gray ME, Rogawski McQuade ET, Scheld WM, Dillingham RA.

BMC Infect Dis. 2018 Oct 24;18(1):532. doi: 10.1186/s12879-018-3408-y.

3.

Etiology of Sepsis in Uganda Using a Quantitative Polymerase Chain Reaction-based TaqMan Array Card.

Moore CC, Jacob ST, Banura P, Zhang J, Stroup S, Boulware DR, Scheld WM, Houpt ER, Liu J.

Clin Infect Dis. 2019 Jan 7;68(2):266-272. doi: 10.1093/cid/ciy472.

4.

Reply to Kuehl et al.

Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Zunt JR, Tunkel AR.

Clin Infect Dis. 2018 Apr 3;66(8):1320-1321. doi: 10.1093/cid/cix985. No abstract available.

PMID:
29126248
5.

Reply to Marx et al.

Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Zunt JR.

Clin Infect Dis. 2017 Oct 15;65(8):1429-1430. doi: 10.1093/cid/cix554. No abstract available.

6.

Evidence of Archaeal Methanogens in Brain Abscess.

Drancourt M, Nkamga VD, Lakhe NA, Régis JM, Dufour H, Fournier PE, Bechah Y, Scheld WM, Raoult D.

Clin Infect Dis. 2017 Jul 1;65(1):1-5. doi: 10.1093/cid/cix286.

PMID:
28379309
7.

Development of a TaqMan Array Card for Acute-Febrile-Illness Outbreak Investigation and Surveillance of Emerging Pathogens, Including Ebola Virus.

Liu J, Ochieng C, Wiersma S, Ströher U, Towner JS, Whitmer S, Nichol ST, Moore CC, Kersh GJ, Kato C, Sexton C, Petersen J, Massung R, Hercik C, Crump JA, Kibiki G, Maro A, Mujaga B, Gratz J, Jacob ST, Banura P, Scheld WM, Juma B, Onyango CO, Montgomery JM, Houpt E, Fields B.

J Clin Microbiol. 2016 Jan;54(1):49-58. doi: 10.1128/JCM.02257-15. Epub 2015 Oct 21.

8.

Toll-like receptor 4 stimulation before or after Streptococcus pneumoniae induced sepsis improves survival and is dependent on T-cells.

Musie E, Moore CC, Martin EN, Scheld WM.

PLoS One. 2014 Jan 21;9(1):e86015. doi: 10.1371/journal.pone.0086015. eCollection 2014.

9.

Mycobacterium tuberculosis bacteremia in a cohort of hiv-infected patients hospitalized with severe sepsis in uganda–high frequency, low clinical suspicion [corrected] and derivation of a clinical prediction score.

Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, Magaret A, Manabe Y, Reynolds SJ, Liles WC, Wald A, Joloba ML, Mayanja-Kizza H, Scheld WM.

PLoS One. 2013 Aug 5;8(8):e70305. doi: 10.1371/journal.pone.0070305. Print 2013. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/0a53f994-bfe2-45db-9dbb-97fdfea023c5.

10.

Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis.

Das R, Koo MS, Kim BH, Jacob ST, Subbian S, Yao J, Leng L, Levy R, Murchison C, Burman WJ, Moore CC, Scheld WM, David JR, Kaplan G, MacMicking JD, Bucala R.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2997-3006. doi: 10.1073/pnas.1301128110. Epub 2013 Jul 23.

11.

Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients.

Doka NI, Jacob ST, Banura P, Moore CC, Meya D, Mayanja-Kizza H, Reynolds SJ, Scheld WM, Yuan W.

PLoS One. 2012;7(10):e48356. doi: 10.1371/journal.pone.0048356. Epub 2012 Oct 29.

12.

The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*.

Jacob ST, Banura P, Baeten JM, Moore CC, Meya D, Nakiyingi L, Burke R, Horton CL, Iga B, Wald A, Reynolds SJ, Mayanja-Kizza H, Scheld WM; Promoting Resource-Limited Interventions for Sepsis Management in Uganda Study Group.

Crit Care Med. 2012 Jul;40(7):2050-8. doi: 10.1097/CCM.0b013e31824e65d7.

13.

Molecular dissection of an outbreak of carbapenem-resistant enterobacteriaceae reveals Intergenus KPC carbapenemase transmission through a promiscuous plasmid.

Mathers AJ, Cox HL, Kitchel B, Bonatti H, Brassinga AK, Carroll J, Scheld WM, Hazen KC, Sifri CD.

MBio. 2011 Nov 1;2(6):e00204-11. doi: 10.1128/mBio.00204-11. Print 2011.

14.

Hypoglycemia at admission is associated with inhospital mortality in Ugandan patients with severe sepsis.

Ssekitoleko R, Jacob ST, Banura P, Pinkerton R, Meya DB, Reynolds SJ, Kenya-Mugisha N, Mayanja-Kizza H, Muhindo R, Bhagani S, Scheld WM, Moore CC.

Crit Care Med. 2011 Oct;39(10):2271-6. doi: 10.1097/CCM.0b013e3182227bd2.

15.

The Infectious Diseases Institute at Makerere University, Kampala, Uganda.

Ronald A, Kamya M, Katabira E, Scheld WM, Sewankambo N.

Infect Dis Clin North Am. 2011 Jun;25(2):369-83. doi: 10.1016/j.idc.2011.02.007.

PMID:
21628052
16.

Infectious disease: do steroids benefit patients with bacterial meningitis?

Quagliarello V, Scheld WM.

Nat Rev Neurol. 2010 Oct;6(10):529-30. doi: 10.1038/nrneurol.2010.132. No abstract available.

PMID:
20927051
17.

Principles of antimicrobial therapy.

Tessier JM, Scheld WM.

Handb Clin Neurol. 2010;96:17-29. doi: 10.1016/S0072-9752(09)96002-X. Epub 2010 Jan 19. Review.

PMID:
20109672
18.

Newer antibacterial drugs for a new century.

Devasahayam G, Scheld WM, Hoffman PS.

Expert Opin Investig Drugs. 2010 Feb;19(2):215-34. doi: 10.1517/13543780903505092. Review.

19.

Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population.

Jacob ST, Moore CC, Banura P, Pinkerton R, Meya D, Opendi P, Reynolds SJ, Kenya-Mugisha N, Mayanja-Kizza H, Scheld WM; Promoting Resource-Limited Interventions for Sepsis Management in Uganda (PRISM-U) Study Group.

PLoS One. 2009 Nov 11;4(11):e7782. doi: 10.1371/journal.pone.0007782.

20.

Training needs assessment for clinicians at antiretroviral therapy clinics: evidence from a national survey in Uganda.

Lutalo IM, Schneider G, Weaver MR, Oyugi JH, Sebuyira LM, Kaye R, Lule F, Namagala E, Scheld WM, McAdam KP, Sande MA.

Hum Resour Health. 2009 Aug 23;7:76. doi: 10.1186/1478-4491-7-76.

21.

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Spellberg B, Talbot GH, Boucher HW, Bradley JS, Gilbert D, Scheld WM, Edwards J Jr, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Clin Infect Dis. 2009 Aug 1;49(3):383-91. doi: 10.1086/600296. Review.

22.

Treatment of severe sepsis with artemether-lumefantrine is associated with decreased mortality in Ugandan patients without malaria.

Moore CC, Jacob ST, Pinkerton R, Banura P, Meya DB, Reynolds SJ, Kenya-Mugisha N, Mayanja-Kizza H, Scheld WM; Promoting Resource-Limited Interventions for Sepsis Management in Uganda (PRISM-U) Study Group.

Am J Trop Med Hyg. 2009 May;80(5):723-8.

PMID:
19407113
23.

The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing.

Al Masalma M, Armougom F, Scheld WM, Dufour H, Roche PH, Drancourt M, Raoult D.

Clin Infect Dis. 2009 May 1;48(9):1169-78. doi: 10.1086/597578.

PMID:
19335164
24.

Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.

Aregawi D, Lopez D, Wick M, Scheld WM, Schiff D.

J Neurooncol. 2009 Sep;94(3):439-43. doi: 10.1007/s11060-009-9878-4. Epub 2009 Mar 31.

PMID:
19333553
25.

An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models.

Moore CC, Martin EN, Lee GH, Obrig T, Linden J, Scheld WM.

BMC Infect Dis. 2008 Oct 20;8:141. doi: 10.1186/1471-2334-8-141.

26.

Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury.

Moore CC, Martin EN, Lee G, Taylor C, Dondero R, Reznikov LL, Dinarello C, Thompson J, Scheld WM.

J Infect Dis. 2008 Nov 1;198(9):1407-14. doi: 10.1086/592222.

27.

Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.

Smith RL, Evans HL, Chong TW, McElearney ST, Hedrick TL, Swenson BR, Scheld WM, Pruett TL, Sawyer RG.

Surg Infect (Larchmt). 2008 Aug;9(4):423-31. doi: 10.1089/sur.2007.024.

28.

The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.

Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ, Kaplan SL, Scheld WM, Whitley RJ; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Aug 1;47(3):303-27. doi: 10.1086/589747.

PMID:
18582201
29.

Outbreak of resistant Pseudomonas aeruginosa infections during a quarterly cycling antibiotic regimen.

Hedrick TL, Schulman AS, McElearney ST, Smith RL, Swenson BR, Evans HL, Truwit JD, Scheld WM, Sawyer RG.

Surg Infect (Larchmt). 2008 Apr;9(2):139-52. doi: 10.1089/sur.2006.102.

PMID:
18426346
30.

A trans-university center for global health.

Lorntz B, Boissevain JR, Dillingham R, Kelly J, Ballard A, Scheld WM, Guerrant RL.

Acad Med. 2008 Feb;83(2):165-72. doi: 10.1097/ACM.0b013e3181609738.

PMID:
18303362
31.

Point-of-care lactate testing predicts mortality of severe sepsis in a predominantly HIV type 1-infected patient population in Uganda.

Moore CC, Jacob ST, Pinkerton R, Meya DB, Mayanja-Kizza H, Reynolds SJ, Scheld WM.

Clin Infect Dis. 2008 Jan 15;46(2):215-22. doi: 10.1086/524665.

PMID:
18171253
32.

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Jan 15;46(2):155-64. doi: 10.1086/524891.

PMID:
18171244
33.

Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.

Spellberg B, Miller LG, Kuo MN, Bradley J, Scheld WM, Edwards JE Jr.

Infection. 2007 Jun;35(3):167-74.

PMID:
17565458
34.

Amikacin and colistin for treatment of Acinetobacter baumannii meningitis.

Fulnecky EJ, Wright D, Scheld WM, Kanawati L, Shoham S.

J Infect. 2005 Dec;51(5):e249-51.

PMID:
15913780
36.

Practice guidelines for the management of bacterial meningitis.

Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ.

Clin Infect Dis. 2004 Nov 1;39(9):1267-84. Epub 2004 Oct 6. No abstract available.

PMID:
15494903
37.

Routine lumbar puncture in children with febrile seizures in Ghana: should it continue?

Owusu-Ofori A, Agbenyega T, Ansong D, Scheld WM.

Int J Infect Dis. 2004 Nov;8(6):353-61.

38.

A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.

Sullivan GW, Fang G, Linden J, Scheld WM.

J Infect Dis. 2004 May 15;189(10):1897-904. Epub 2004 Apr 28.

PMID:
15122527
39.

Reducing joint destruction due to septic arthrosis using an adenosine2A receptor agonist.

Cohen SB, Gill SS, Baer GS, Leo BM, Scheld WM, Diduch DR.

J Orthop Res. 2004 Mar;22(2):427-35.

40.

W Michael Scheld--President of the Infectious Diseases Society of America interview by Pam Das.

Scheld WM.

Lancet Infect Dis. 2003 Oct;3(10):667-70. No abstract available.

PMID:
14522267
41.

A pseudo-outbreak of nosocomial infections associated with the introduction of an antibiotic management programme.

Calfee DP, Brooks J, Zirk NM, Giannetta ET, Scheld WM, Farr BM.

J Hosp Infect. 2003 Sep;55(1):26-32.

PMID:
14505606
42.

Whipple disease of the central nervous system.

Scheld WM.

J Infect Dis. 2003 Sep 15;188(6):797-800. Epub 2003 Sep 9. Review. No abstract available.

PMID:
12964109
43.
44.

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Clin Infect Dis. 2003 May 15;36(10):1221-8. Epub 2003 May 8.

PMID:
12746765
45.

Treatment of Salmonella meningitis: two case reports and a review of the literature.

Owusu-Ofori A, Scheld WM.

Int J Infect Dis. 2003 Mar;7(1):53-60. Review.

46.
47.
48.

Pathogenesis and pathophysiology of pneumococcal meningitis.

Koedel U, Scheld WM, Pfister HW.

Lancet Infect Dis. 2002 Dec;2(12):721-36. Review.

PMID:
12467688
49.

Corticosteroids for everyone with meningitis?

Tunkel AR, Scheld WM.

N Engl J Med. 2002 Nov 14;347(20):1613-5. No abstract available.

PMID:
12432049
50.

Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury.

Scheld WM, Koedel U, Nathan B, Pfister HW.

J Infect Dis. 2002 Dec 1;186 Suppl 2:S225-33. Review.

PMID:
12424702

Supplemental Content

Loading ...
Support Center